International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-6 doi: https://doi.org/10.5281/zenodo.14207834
Original Research Article
CRP Levels in PCOS-IR Rat Models (Rattus norvegicus) After Administration of Moringa oleifera Extract
Published
Nov. 23, 2024
Abstract

Polycystic Ovarian Syndrome (PCOS) is a metabolic syndrome affecting women’s reproductive health. PCOS is diagnosed using Rotterdam Criteria, and is often associated with insulin resistance. PCOS with insulin resistance (PCOS-IR) can both induce inflammation, in which the inflammation itself can worsen PCOS-IR. Moringa oleifera is a plant tested for its anti-inflammatory and anti-oxidant properties from pytochemicals that can be found in it. Aim: This research aims to study the effect of Moringa oleifera leaf extract administration to PCOS-IR rat models towards levels of C-reactive protein (CRP), a widely known biomarker of inflammation. Method: Female Wistar rats were divided into 3 groups (n=10): normal rats, PCOS-IR rats and PCOS-IR rats administered with 500 mg/kg Moringa oleifera leaf extract. PCOS rat model is created by injecting 1 mg / 100 gr testosterone proprionate for 21 days, and another 21 days for Moringa oleifera leaf extract administration. Blood is then collected and tested for CRP, and data collected will be statistically processed. Results: The PCOS-IR group showed increase in CRP level compared to control group, and the Moringa oleifera treated group showed significantly lower CRP level compared to PCOS group. The CRP level in Moringa oleifera treated group comes near to that of control group. Conclusion: Consumption of Moringa oleifera leaves can reduce inflammation in PCOS-IR shown by significant decrease of CRP levels.

Recommended Articles
Loading Image...
Volume-5, Issue-6
Citations
1102 Views
52 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved